B of A Securities analyst Jason Gerberry initiates coverage on Amphastar Pharma (NASDAQ:AMPH) with a Neutral rating and announces Price Target of $63.
B of A Securities Initiates Coverage On Amphastar Pharma With Neutral Rating, Announces Price Target of $63
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.